Heptares: Ledger

Stories naming Heptares. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Investor	Rounds	Invested
No investors recorded yet. Know one?

Company	Kind	Announced	Price	Sources
Heptares is not recorded as having acquired anything.

Name	Role	Sources
Dr Roberto Solari	Founder	Brandon Capital portfolio, Brandon BioCatalyst portfolio

Seed $8.2m

Myricx Pharma Launches with £4.5M (AU$8.2M) Financing to Progress its Novel NMT inhibitors in Cancer

UK biotech Myricx Pharma launched with a £4.5 million seed round from Sofinnova Partners and Brandon Capital to advance its NMT-inhibitor cancer drug discovery work.

Brandon BioCatalyst portfolio Mon 16 Nov 2020 Myricx Pharma Charles Consultants GSK Heptares Medical Research Commercialisation Fund (MRCF)Pfizer Brandon Capital Partners Sofinnova Partners Dr Andrew Bell Prof Ed Tate Maina Bhaman Dr Roberto Solari Dr Robin Carr Dr Stephen Thompson Sue Charles

Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio

Heptares

Funding history

Investors

What Heptares bought

People

Coverage

Myricx Pharma Launches with £4.5M (AU$8.2M) Financing to Progress its Novel NMT inhibitors in Cancer